Travere Therapeutics (TVTX) Intangibles (2013 - 2026)

Travere Therapeutics has reported Intangibles for 14 years, with the latest figure at $110.0 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles rose 5.99% year-over-year to $110.0 million; the trailing twelve-month figure through Mar 2026 stood at $110.0 million (up 5.99% YoY), and the FY2025 full-year result was $113.9 million, up 9.52% from the prior year.
• Intangibles for Q1 2026 stood at $110.0 million, down from $113.9 million in the prior quarter.
• The five-year high for Intangibles was $162.9 million in Q1 2023, with the low at $97.1 million in Q4 2022.
• Historically, Intangibles has averaged $119.8 million across 5 years, with a median of $106.9 million in 2023.
• Annual changes were most pronounced in 2024 — Intangibles tumbled 37.88% — and 2025, when it gained 9.52%.
• Travere Therapeutics' Intangibles stood at $97.1 million in 2022, then advanced by 7.59% to $104.4 million in 2023, then decreased by 0.45% to $104.0 million in 2024, then gained by 9.52% to $113.9 million in 2025, then declined by 3.36% to $110.0 million in 2026.
• The last three Intangibles figures came in at $110.0 million (Q1 2026), $113.9 million (Q4 2025), and $109.4 million (Q3 2025), per Business Quant data.